Targets › IL13RA1
1 program from 1 company in 4 trials: 4 Phase 1; Oncology; next expected readout Dec 2027.
Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. (UniProt, P78552)
Open in Phaseline: the race on IL13RA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| M.D. Anderson Cancer Center | Cytokine-treated Veto Cells CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel | IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2 | Phase 1 | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal Cancer | Dec 2027 |
Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1) Phase 1 (1) Colorectal Cancer (1)
mixed (1)
M.D. Anderson Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.